• 1. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Dialkyl ethers
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Dialkyl ethers

Recent Advances in the Application of Ethyl 2-[2-[2-(2-Hydroxyethoxy)ethoxy]ethoxy]acetate (CAS 118988-04-8) in Chemical Biology and Pharmaceutical Research

Ethyl 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]acetate (CAS 118988-04-8) has recently emerged as a compound of significant interest in chemical biology and pharmaceutical research. This polyethylene glycol (PEG)-based derivative has shown remarkable potential in drug delivery systems, bioconjugation chemistry, and as a building block for more complex pharmaceutical compounds. The unique structural features of this compound, including its hydrophilic PEG chain and terminal ester group, make it particularly valuable for modifying the physicochemical properties of drug molecules.

Recent studies have focused on utilizing ethyl 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]acetate as a linker molecule in antibody-drug conjugates (ADCs). Research published in the Journal of Medicinal Chemistry (2023) demonstrated its effectiveness in connecting cytotoxic payloads to monoclonal antibodies while maintaining stability in circulation and allowing for controlled release at target sites. The compound's optimal chain length and hydrophilicity were found to significantly improve the pharmacokinetic properties of the resulting ADCs compared to traditional linker systems.

In polymer chemistry, this compound has been investigated as a key intermediate for synthesizing biodegradable PEG-based hydrogels. A 2024 study in Biomaterials Science reported its use in creating injectable hydrogels with tunable mechanical properties and degradation rates, showing promise for tissue engineering applications. The researchers highlighted the compound's versatility in forming both physical and chemical crosslinks, enabling precise control over hydrogel properties.

From a synthetic chemistry perspective, novel catalytic methods have been developed for the efficient production of ethyl 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]acetate. A recent breakthrough published in Organic Process Research & Development (2024) described a green chemistry approach using enzyme-catalyzed esterification, achieving higher yields (92%) and purity (>99%) compared to traditional synthetic routes. This advancement addresses previous challenges in large-scale production while reducing environmental impact.

Pharmacological studies have revealed interesting properties of derivatives based on this compound. Research in Molecular Pharmaceutics (2023) demonstrated that conjugates containing ethyl 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]acetate moieties showed enhanced blood-brain barrier penetration compared to their parent compounds. This finding opens new possibilities for central nervous system drug development, particularly for neurodegenerative diseases where drug delivery remains a major challenge.

Looking forward, the unique properties of ethyl 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]acetate (CAS 118988-04-8) position it as a valuable tool in pharmaceutical innovation. Current research directions include its application in mRNA delivery systems, targeted cancer therapies, and as a component of smart drug delivery platforms responsive to specific physiological stimuli. As synthetic methods continue to improve and our understanding of its biological interactions deepens, this compound is expected to play an increasingly important role in advancing therapeutic technologies.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)